Simon Stern

Consultant Haematologist. Interested in haemato-oncology in general and multiple myeloma in particular.

[Muzaffar Qazilbash @Transplant_Doc]

MajesTEC-9 trial: Teclistamab vs. VPd or Kd in RRMM, 1-3 prior lines. N=593, median F/U: 17.3 months. 18-month PFS 70% vs. 27%, HR: 0.29. 41% grade 3-4 infections, 6.5% deaths in Teclistamab arm #mmsm #ASCO26 @NEJM https://t.co/I4kSOdeoL3

[Gurbakhash Kaur @GKaurMD]

ERASMM Study: Elra In High Risk Smoldering MM
n= 76

Safety: Gr 3 CRS in 2 pts & No ICANS. 70% recd toci, , Infxn: 14% w/ Gr 3
Efficacy:
ORR: 90%, CR 30%;
Median F/U of 14 m: 72% CR rate; MRD rate 90% in evaluable pts
Responses deepened over time.

#mmsm #ASCO2026

[Raj Chakraborty @rajshekharucms]

Since management of High Risk-Smoldering Multiple #Myeloma often comes up in clinic these days (and leads to spirited discussions with trainees and colleagues), sharing my approach here on how I counsel patients on the use of single-agent daratumumab.

I am genuinely excited though about fixed-duration BCMA BsAbs in selected patients, and looking forward to more data in coming years!

[Dr Rishabh Jain @DrRishabhOnco]

AI reads almost everything.
But medicine is still practiced in the space between evidence and judgment.

That space remains profoundly human.

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

1/ 🧵 ANDROMEDA final analysis is practice-changing for newly diagnosed AL amyloidosis.

IMPORTANT tweets: 3/4 and 6 for clinicians who treats Amyloidosis

D-VCd = daratumumab + bortezomib/cyclophosphamide/dexamethasone.

With 61.4 months median follow-up, D-VCd improved depth of response, organ recovery, MOD-PFS, and OS. 🔥
#USMIRC #MedEd #medtwitter #mmsm #myeloma @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @OncoAlert

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

2/ Key efficacy signal:

✅ Hematologic CR: 59.5% with D-VCd vs 19.2% with VCd
✅ OR 6.03; P<0.0001
✅ VGPR or better: 79.0% vs 50.3%

This is not just more responses — it is deeper responses. 🎯

#USMIRC #MedEd #medtwitter #mmsm #myeloma @U@USMIRCNEWS @US_HMC @MedwatchKate @Larvol @OncoAlert

[Sarmo ⚫️🟠 @sarm0161]

I’m pleased to report that yesterdays VAR decision has made its ways to the hellhole that is LinkedIn.

[Simon Stern @DrSStern]

Intriguing paper in
@ASHbloodjournal suggesting the delayed development of MRD negativity in transplant-eligible newly diagnosed myeloma patients with t(11:14) does not prevent the translocation's good prognosis.
https://t.co/ie6H5zOBYc

[Raj Chakraborty @rajshekharucms]

Glad this negative study was published by the @iStopMM group! No association of any dietary pattern with MGUS overall in this large population-based screening study. Before putting the burden of dietary intervention on our patients (beyond common sense), we must have randomized trials with clinically relevant endpoints.

[Paul Bronks @SlenderSherbet]

Yes you can come, just don't be weird.

Me:

[Martin Kaiser @MyMKaiser]

Precision medicine in #myeloma demands precision imaging: is whole body MRI #WBMRI the solution?
@ProfMessiou
https://t.co/BuhLKrR10E

[Raj Chakraborty @rajshekharucms]

Grateful to @ASHClinicalNews for highlighting our article on sFLC>100 criterion for #Myeloma diagnosis!
This creates two problems: Potential over-treatment of a majority of patients in a heterogeneous group & driving PFS benefit in high-risk smoldering myeloma trials by events that are not clinically meaningful!

[Khushali Jhaveri @JhaveriKhushali]

As BsAbs move into earlier lines, infection risk is the elephant in the room!

Kim et al. @BloodAdvances: 75% cumulative infection rate at 24 mo.

Neutropenia and low IgG drove risk, early steroids did not.

IgG monitoring and timely IVIG remain key!

https://t.co/nT0q9VQZmv

[Vincent Rajkumar @VincentRK]

Just in: Good news for the myeloma field.

FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy.
Note: Always use Tec-Dara with monthly IVIG. It’s not optional.

That was fast! And this is unprecedented curve is why.

[- @HaIfTurn]

Tottenham fans next season

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Picture worth a thousand words!

@AjHematology by Mayo myeloma: RW Dara-Rd in #MMsm

1️⃣ 2/3 pts required dose ⬇️, typically #downwithdex or #downwithlen

2️⃣ Landmarked PFS unequivocally better if so

My takeaway: Duration of Dara-Rd --&gt; Dara(±R) more important than exact dose!

[Simon Stern @DrSStern]

@mancunianmedic He was a patient of mine for a few years. He had a great self-deprecating sense of humour, particularly if he didn't think much of the play/programme he was involved with when I saw him.

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Real-world analysis of resuming bone-modifying agents in relapsed myeloma does not show improvement in long-term survival outcomes (median PFS 10.1 vs 9.2 months; OS 39.6 vs 51.5 months for deferred vs. BMA-received pts): https://t.co/uu8WW8HxFm. #mmsm

[Simon Stern @DrSStern]

Fascinating bit of social history.

[Then/Now @xThen_Now]

How couples met (1930-2024)

[Simon Stern @DrSStern]

Excellent editorial by @DrRakeshPopat, re-evaluating the place of bispecific antibody therapy in the light of the groundbreaking MajesTEC-3 trial. #mmsm
Biting the Tail of CAR-T for Relapsed Multiple Myeloma | New England Journal of Medicine https://t.co/ILMMGme8o6